NCT04320485View on ClinicalTrials.gov

Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)

CompletedOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

March 25, 2020

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions
Anthrax
Interventions
DIAGNOSTIC_TEST

Active Anthrax Detect™ Plus (AAD Plus)

A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.

Trial Locations (4)

43214

Hometown Urgent Care and Research, Columbus

45215

Hometown Urgent Care and Research, Cincinnati

45424

Hometown Urgent Care and Research, Dayton

85283

Fiel Family and Sports Medicine/CCT Research, Tempe

Sponsors
All Listed Sponsors
collaborator

Fast-Track Drugs & Biologics, LLC

UNKNOWN

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

InBios International, Inc.

INDUSTRY

NCT04320485 - Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI) | Biotech Hunter | Biotech Hunter